NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 85 filers reported holding NGM BIOPHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $167,000 | +26.5% | 12,757 | +23.6% | 0.00% | – |
| Q2 2022 | $132,000 | -48.6% | 10,325 | +14.8% | 0.00% | – |
| Q1 2021 | $257,000 | -24.4% | 8,996 | -20.4% | 0.00% | – |
| Q4 2020 | $340,000 | +37.1% | 11,302 | -26.4% | 0.00% | – |
| Q3 2020 | $248,000 | +17.0% | 15,347 | +42.7% | 0.00% | – |
| Q2 2020 | $212,000 | +57.0% | 10,756 | 0.0% | 0.00% | – |
| Q1 2020 | $135,000 | -28.9% | 10,756 | +3.7% | 0.00% | – |
| Q4 2019 | $190,000 | -47.7% | 10,371 | -60.5% | 0.00% | -100.0% |
| Q3 2019 | $363,000 | – | 26,236 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 16,245,817 | $247,749,000 | 45.93% |
| Ponoi II Management, LLC | 1,298,908 | $19,808,000 | 43.96% |
| RHO CAPITAL PARTNERS INC | 3,766,666 | $57,442,000 | 39.74% |
| Ponoi Management, LLC | 1,298,908 | $19,808,000 | 25.71% |
| Euclidean Capital LLC | 746,674 | $11,387,000 | 6.62% |
| StepStone Group LP | 1,573,357 | $23,994,000 | 1.79% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 200,494 | $3,058,000 | 1.26% |
| First Light Asset Management, LLC | 816,653 | $12,454,000 | 1.10% |
| BVF INC/IL | 955,000 | $14,564,000 | 0.58% |
| HighVista Strategies LLC | 46,243 | $705,000 | 0.45% |